References
- Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
- June CH, Maus MV, Plesa G, et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014;63(9):969–975. doi:10.1007/s00262-014-1568-1
- Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
- Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954
- June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280):280ps7. ** Comprehensive review of current issues in the field with analysis of current challenges and perspectives. doi:10.1126/scitranslmed.aaa3643
- Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21:914–921. doi:10.1038/nm.3910
- Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–1027. * First report and updated data of TCR-redirected ACT against sarcomas. doi:10.1158/1078-0432.CCR-14-2708
- Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151. doi:10.1097/CJI.0b013e3182829903
- Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–1683. doi:10.1056/NEJMoa1106152
- Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;2765319: 1719–1724. doi:10.1126/science.276.5319.1719
- Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109(6):2331–2338. doi:10.1182/blood-2006-05-023069
- Voss R-H, Thomas S, Pfirschke C, et al. Coexpression of the T-cell receptor constant domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood. 2010;115(25):5154–5163. doi:10.1182/blood-2009-11-254078
- Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807–815. doi:10.1038/nm.2700
- Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009;69(23):9003–9011. doi:10.1158/0008-5472.CAN-09-1450
- Thomas S, Xue S-A, Bangham CR, et al. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood. 2011;118(2):319–329. doi:10.1182/blood-2010-12-326736
- Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. * Important report and mechanistic analysis of severe CAR-mediated toxicity. doi:10.1182/blood-2013-03-490565
- Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. * Important clinical data reporting efficacy, persistance and toxicities of CAR-redirected ACT against leukemia. doi:10.1126/scitranslmed.3002842
- Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733. * Important clinical data reporting efficacy, persistance and toxicities of CAR-redirected ACT against CLL. doi:10.1056/NEJMoa1103849
- Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. * Important clinical data reporting efficacy, persistance and toxicities of CAR-redirected ACT against ALL. doi:10.1056/NEJMoa1215134
- Leuci V, Mesiano G, Gammaitoni L, et al. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr Gene Ther. 2014;14(1):52–62.
- Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 2006;66(11):5927–5933. doi:10.1158/0008-5472.CAN-06-0130